TrialsgrambetaRCTs are beautiful

iDCL / DCLP3

2019

Six-Month Randomised Trial of a Closed-Loop System in Type 1 Diabetes

In 168 patients aged 14–71 with type 1 diabetes, hybrid closed-loop insulin delivery (Control-IQ) improved time-in-range and HbA1c compared with sensor-augmented pump therapy.

Result

Time in 70–180 mg/dL range
Absolute difference
12 points
NNT
9
Effect estimate

difference (pp)11P < 0.001

Absolute difference and NNT are derived from the event rates.

Also reported: HbA1c difference −0.3 %; no severe hypoglycaemia.

Original publication
Subtopic
Hybrid closed-loop insulin
Design
Open-label RCT, 6 mo
Relevance
Supporting: context rather than must-know.
Source
Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717.doi 10.1056/NEJMoa1907863

Discussion & critique

Basis of the FDA clearance of Control-IQ. Hybrid closed-loop systems are now standard of care for T1DM in many countries.